DaVita Clinical Research Central Laboratory Expands Its Services and Technology
September 15 2011 - 9:00AM
Business Wire
DaVita Clinical Research® (DCR®), a provider of clinical
research services focused on kidney research as well as a multitude
of specialty therapeutic populations, has announced the company’s
expansion within its Central Laboratory.
DCR’s Central Laboratory is focused on providing world-class
clinical research in both complex/specialty populations and
therapeutic areas, as well as chronic kidney disease (CKD)
populations. By year’s end, the lab’s test menu will increase by 43
percent, maintaining the company’s leadership position in advanced
renal care while ensuring critical coverage in the areas of
oncology, immunology, endocrinology, cardiology and anemia.
The testing facility has expanded its technology through the
addition of two new testing platforms, the IMMULITE 2000 XPi
Immunoassay System and the AB SCIEX QTRAP 5500 LC/MS/MS system.
Other additions include increased specimen management and storage
capabilities for both short- and long-term testing. The Central
Laboratory facilitates satisfaction with continuous IT
advancements, allowing for clean, timely data and ease of customer
access to laboratory results. DCR’s commitment to “Excellence
Through Innovation” is evident by its continual, selective
additions of scientific and operational staff coming from the CRO
and pharma communities.
In addition, DCR recently announced the launch of its
Biorepository Services. The biorepository contains collections of
biological material and their pertinent databases that are
systemized for the purpose of research. This new, one-of-a-kind,
state-of-the-art biorepository dramatically improves the odds of a
breakthrough discovery by combining samples meticulously collected
from our nationwide network of over 1,700 sites richly annotated
with patient-level heath information.
“We are proud of our recent investments in equipment and assay
development,” stated DCR Vice President of Commercial Development
Kevin J. Goudreau. “These investments will allow us to supply
central laboratory services outside of renal care. We will continue
to invest heavily in assay development until the breadth of
our offering covers virtually all therapeutic indications.”
DaVita and DCR are trademarks or registered trademarks of DaVita
Inc. All other trademarks are the property of their respective
owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) is committed to advancing the
knowledge and practice of kidney care. DCR brings unsurpassed
knowledge, skill, and expertise to pharmaceutical research,
ensuring the success of their clients’ clinical trials. DCR’s
clinical expertise ranges from designing the study to preparing and
submitting the final report. DCR’s Early Clinical Research unit
(Phase I-IIa) and Clinical Development network of physicians and
investigative sites, Health Economics and Central Laboratory are
focused on providing world-class clinical research in both
complex/specialty populations and therapeutic areas as well as CKD
and ESRD populations needed to meet clinical goals. To learn more
about DCR, visit www.davitaclinicalresearch.com.
About DaVita
DaVita Inc. (NYSE: DVA), a Fortune 500® company, is a leading
provider of kidney care in the United States, delivering dialysis
services to patients with chronic kidney failure and end stage
renal disease. DaVita strives to improve patients’ quality of life
by innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of June 30, 2011, DaVita operated or provided
administrative services at 1,669 dialysis facilities, serving
approximately 131,000 patients. DaVita supports numerous programs
dedicated to creating positive, sustainable change in communities
around the world. The company’s leadership development initiatives
and social responsibility efforts have been recognized by Fortune,
Modern Healthcare, Newsweek and WorldBlu. For more information,
please visit www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024